scholarly journals Chronic kidney disease is associated with increased risk of sudden sensorineural hearing loss and Ménière’s disease: a nationwide cohort study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jong-Yeup Kim ◽  
Suehyun Lee ◽  
Jaehun Cha ◽  
Gilmyeong Son ◽  
Dong-Kyu Kim
Keyword(s):  
Chronic Kidney Disease ◽  
Hearing Loss ◽  
Kidney Disease ◽  
Meniere’S Disease ◽  
Sudden Sensorineural Hearing Loss ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Ménière's Disease

AbstractSeveral studies have demonstrated the harmful effects of chronic kidney disease (CKD) on the audiovestibular system. Through a time-to-event analysis, we aimed to compare the association of CKD with sudden sensorineural hearing loss (SSNHL), and Ménière’s disease against a control population without CKD. We used a total of 1,025,340 patients from the Korean National Health Insurance Service database from 2002 to 2013. The CKD group (n = 2572) included patients diagnosed with CKD more than three times between January 2003 and December 2005. The non-CKD group (n = 5144) consisted of two patients without CKD for every patient with CKD. Each patient was monitored until December 2013. We calculated the incidence, survival rate, and hazards ratio (HR) of SSNHL and Ménière’s disease. In the CKD group, the incidence of SSNHL and Ménière’s disease was 1.39 and 3.64 per 1000 person-years, respectively. Patients with CKD showed an adjusted HR of 2.15 and 1.45 for SSNHL and Ménière’s disease, respectively. Middle-aged patients with CKD were associated with a higher incidence of developing SSNHL and Ménière’s disease than those without CKD. Female patients with CKD had a higher risk of developing SSNHL; however, there was no significant difference in the risk of Ménière’s disease in patients with CKD according to sex. Our findings suggest that CKD is associated with an increased incidence of SSNHL and Ménière’s disease. Therefore, audiovestibular surveillance should be considered in patients with CKD.

scholarly journals Mining Immune Epitopes in Ménière’s Disease and Sudden Sensorineural Hearing Loss

2012 ◽  
Vol 147 (2_suppl) ◽  
pp. P89-P89
Author(s):  
Michael P. Platt ◽  
Alphi P. Elackattu ◽  
Sonam Dilwali ◽  
Jignesh Parikh ◽  
Konstantina M. Stankovic
Keyword(s):  
Hearing Loss ◽  
Sensorineural Hearing Loss ◽  
Meniere’S Disease ◽  
Sudden Sensorineural Hearing Loss ◽  
Sensorineural Hearing ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Ménière's Disease

scholarly journals Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière’s Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Augusto Pietro Casani ◽  
Elena Navari ◽  
Giorgio Guidetti ◽  
Michel Lacour
Keyword(s):  
Hearing Loss ◽  
Meniere’S Disease ◽  
Consensus Conference ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Clinical Approach ◽  
Menière's Disease ◽  
Delphi Consensus ◽  
Ménière's Disease

Menière’s disease is a disorder of the inner ear that causes vertigo, tinnitus, fullness, and hearing loss. Several pharmacological treatments are available, but none of them has shown significant results. Betahistine has been largely used but its effect on the main symptoms of Menière’s disease remains unclear. In order to improve clinical appropriateness and to reduce the heterogeneity of the therapeutic approaches for Menière’s disease, we proposed a European Consensus Conference on Betahistine’s prescription. A group of European experts in vestibular disorders completed a questionnaire, prepared by opinion leaders, on the use of betahistine in Menière’s disease. The Delphi method was used as an iterative investigation method in order to increase and establish the consensus. While betahistine was considered useful to reduce the number of the vertigo attacks during the intercritical phase of the disease, its use during attacks was considered helpful only when associated with other drugs. Betahistine was not considered useful for preventing hearing loss. The experts support the use of betahistine during the intercritical phase of the disease to reduce the number and severity of vertigo episodes. They also defined the parameters for a good clinical approach to evaluate the efficacy of betahistine treatment for Menière’s disease.

Drug treatment of vertigo and ménière’s disease cinnarizine and betahistine

1981 ◽  
Vol 19 (5) ◽  
pp. 17-18
Keyword(s):  
Hearing Loss ◽  
Drug Treatment ◽  
Vestibular Function ◽  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Menière's Disease ◽  
Ménière's Disease ◽  
Attacks Of Vertigo

Vertigo and dizziness are major symptoms of disturbed vestibular function. Sudden attacks of vertigo, associated with tinnitus and sensorineural hearing loss, occur in a wide variety of disorders of the inner ear, and when no underlying cause can be found the condition is termed ménière’s disease.

scholarly journals Meniere's Disease of Syphilitic Etiology

1997 ◽  
Vol 76 (8) ◽  
pp. 508-527 ◽  
Author(s):  
Jack L. Pulec
Keyword(s):  
Hearing Loss ◽  
Specific Treatment ◽  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Shunt Operation ◽  
Menière's Disease ◽  
Ménière's Disease ◽  
Ear Symptoms

Congenital or acquired syphilis is the cause of Meniere's disease in six percent of all cases. The pathogenesis is endolymphatic hydrops and osteitis of the otic capsule which produces the characteristic fluctuating hearing loss, tinnitus and ear pressure associated with episodic spells of vertigo. The ear symptoms are, at first, typical of Meniere's disease of other etiologies. Failure to establish the specific etiologic diagnosis can result in unnecessary surgical treatment or inappropriate medical therapy. In some cases, if a steroid, the specific treatment, is not given promptly, hearing can be quickly and permanently lost. The etiology is confirmed by obtaining a reactive fluorescent treponema antibody absorption (FTA-abs) test. The clinical features and natural history of Meniere's disease of syphilitic etiology are unique. Ear symptoms often begin in the fifth decade of life, first in one ear and, after a few years, involving the second ear. Reduced or absent caloric responses are characteristic. When hearing loss is severe and sudden, this condition represents a true medical emergency and should be treated with prompt administration of steroids. An endolymphatic subarachnoid shunt operation is occasionally necessary as adjunctive management. An analysis of 34 cases shows that long-term use of steroids can maintain effective hearing for more than 20 years.

MicroRNA Profiling as a Methodology to Diagnose Ménière’s Disease: Potential Application of Machine Learning

2020 ◽  
pp. 019459982094064
Author(s):  
Matthew Shew ◽  
Helena Wichova ◽  
Andres Bur ◽  
Devin C. Koestler ◽  
Madeleine St Peter ◽  
...  
Keyword(s):  
Machine Learning ◽  
Hearing Loss ◽  
Meniere’S Disease ◽  
Menière’S Disease ◽  
Classification Model ◽  
Meniere's Disease ◽  
Ménière’S Disease ◽  
Classification Models ◽  
Menière's Disease ◽  
Ménière's Disease

Objective Diagnosis and treatment of Ménière’s disease remains a significant challenge because of our inability to understand what is occurring on a molecular level. MicroRNA (miRNA) perilymph profiling is a safe methodology and may serve as a “liquid biopsy” equivalent. We used machine learning (ML) to evaluate miRNA expression profiles of various inner ear pathologies to predict diagnosis of Ménière’s disease. Study Design Prospective cohort study. Setting Tertiary academic hospital. Subjects and Methods Perilymph was collected during labyrinthectomy (Ménière’s disease, n = 5), stapedotomy (otosclerosis, n = 5), and cochlear implantation (sensorineural hearing loss [SNHL], n = 9). miRNA was isolated and analyzed with the Affymetrix miRNA 4.0 array. Various ML classification models were evaluated with an 80/20 train/test split and cross-validation. Permutation feature importance was performed to understand miRNAs that were critical to the classification models. Results In terms of miRNA profiles for conductive hearing loss versus Ménière’s, 4 models were able to differentiate and identify the 2 disease classes with 100% accuracy. The top-performing models used the same miRNAs in their decision classification model but with different weighted values. All candidate models for SNHL versus Ménière’s performed significantly worse, with the best models achieving 66% accuracy. Ménière’s models showed unique features distinct from SNHL. Conclusions We can use ML to build Ménière’s-specific prediction models using miRNA profile alone. However, ML models were less accurate in predicting SNHL from Ménière’s, likely from overlap of miRNA biomarkers. The power of this technique is that it identifies biomarkers without knowledge of the pathophysiology, potentially leading to identification of novel biomarkers and diagnostic tests.

Sign in / Sign up

Export Citation Format

Share Document